Please login to the form below

Not currently logged in
Email:
Password:

iGlarLixi

This page shows the latest iGlarLixi news and features for those working in and with pharma, biotech and healthcare.

FDA clears rival diabetes combos from Sanofi and Novo Nordisk

FDA clears rival diabetes combos from Sanofi and Novo Nordisk

In almost a mirror image, Sanofi's Soliqua (variously known as iGlarLixi and LixiLan) combines top-selling basal insulin Lantus (insulin glargine) – albeit now facing biosimilar competition in some markets - and

Latest news

  • Sanofi trumpets new IGlarLixi data after regulatory delay Sanofi trumpets new IGlarLixi data after regulatory delay

    Sanofi is highlighting new data for its IGlarLixi combination drug for diabetes showing it is more effective at controlling mealtime blood glucose than its Lantus blockbuster. ... The FDA scuppered those plans last month by announcing a delay of up to

  • Sanofi loses lead on diabetes combo IGlarLixi after FDA delay Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

    The FDA has asked for more information on Sanofi and Zealand Pharma's IGlarLixi combination drug for diabetes, giving a rival drug from Novo Nordisk a chance to be first to ... The FDA is due to deliver a verdict on Xultophy next month, with a decision

  • Sanofi boosted by iGlarLixi trials at ADA Sanofi boosted by iGlarLixi trials at ADA

    Sanofi's combination insulin/GLP-1 agonist drug iGlarLixi (formerly LixiLan) has met objectives in two phase III trials, setting up a showdown in the diabetes market. ... The positive data comes as iGlarLixi approaches an FDA decision on approval - due

  • FDA panel backs Sanofi's insulin/GLP-1 agonist combo FDA panel backs Sanofi's insulin/GLP-1 agonist combo

    The FDA panel voted 12 to 2 in favour of approval for iGlarLixi - a combination of insulin glargine and GLP-1 agonist lixisenatide - as an adjunct to diet and exercise to ... iGlarLixi and other new drugs such as longer-acting Lantus follow-up Toujeo are

  • FDA advisors back Novo Nordisk's IDeglira combination FDA advisors back Novo Nordisk's IDeglira combination

    The committee's decision could also give Novo a boost over its diabetes rival Sanofi, whose similar combination of iGlarLixi (which brings together Lantus and Lyxumia) is due to be reviewed

More from news
Approximately 4 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics